Covid19EXER-COVIDNCT04797871
Resistance Training and Clinical Status in Patients With Post Discharge Symptoms After Covid-19
A study testing Resistance training in people with Covid19 and SARS-CoV2, run by Universidad Pública de Navarra at 1 site in Spain.
Trial summary
COVID-19 survivors commonly exhibit a marked extra-respiratory complication affecting the cardiac (arrhythmias and myocardial injury), renal (acute kidney injury), gastrointestinal, nervous (neuropathy, encephalopathy), endocrine and musculoskeletal (weakness, pain, and fatigue) systems. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Covid19, SARS-CoV2, Fatigue Syndrome, Chronic
- What is being tested?
- Resistance training
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteSpain
- Study dates
- 8 Mar 2021to 18 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age ≥ 18 years
- SARS-CoV-2 diagnosed using real-time reverse transcriptase polymerase chain reaction (PCR) tests or positive for SARS-CoV-2 virus antigen >90 days before randomization.
- Still present a chronic symptomatic phase lasting >90 days since debut of symptoms.
- Have not been hospitalized.
- There is no evidence on clinical records of pneumonia or any other organ failure related to SARS-CoV-2.
- Capable and willing to provide an informed consent.
Who cannot join
- Pregnancy or breast-feeding.
- Present atrial fibrillation.
- Diagnosed with acute myocarditis.
- Health conditions that prevent participating in the exercise intervention
- Patients who cannot undergo VO2max (e.g. acute heart attack or unstable angina, aortic stenosis, acute endocarditis / pericarditis, uncontrolled high blood pressure, acute thromboembolism, severe heart failure, respiratory failure and uncontrolled acute decompensated diabetes mellitus or low blood sugar).
- Treatment with IL-6 receptor antagonists (tocilizumab, kevzara) within the last month due to drug interference with the cardiopulmonary exercise adaptations.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Resistance Training Intervention on the Clinical Status in Patients With Post Discharge Symptoms After Covid-19: The "EXER-COVID Study"
COVID-19 survivors commonly exhibit a marked extra-respiratory complication affecting the cardiac (arrhythmias and myocardial injury), renal (acute kidney injury), gastrointestinal, nervous (neuropathy, encephalopathy), endocrine and musculoskeletal (weakness, pain, and fatigue) systems. In this context, several studies have found that resistance training intervention promotes important health-related benefits, including cardiac function, compared to aerobic exercise training. Other exercise adaptations include increased skeletal muscle metabolism function, yet physio/psychological adaptations are known to be limited in COVID-19 survivors. Hence, given that resistance training intervention is implemented in a manner that is tolerable to the individual patient, it may be a potential beneficiary "personalized" rehabilitation treatment for patients with COVID-19 syndrome ambulatory.
The "EXER-COVID Clinical Study" project aims at determining the role of personalized exercise intervention in the treatment of post-COVID-19 syndrome ambulatory patients.
Read the detailed description
100 patients will be recruited and undergo baseline testing, including examination, immune systems, biochemistry markers, ECG, DXA, metabolic/respiratory function, VO2max, muscular fitness, lipidomic/inflammatory/oxidative markers and psychological outcomes.
After baseline testing, participants will be randomly allocated into one group receiving standard of care (control group) or a group performing personalized resistance training intervention two times a week over a period of 6 weeks. The randomization procedure involves a computer-generated block randomization schedule in a ratio of 1:1 stratified by an independent person. Following the 8-week intervention period (with a 1-week washout period), both groups will complete a series of follow-up tests (as baseline testing). A 12-week follow-up experimental day is also planned in order to evaluate physio/psychological changes.
- Being tested
- Resistance training, Standard care
- Medical subject headings
- COVID-19, Fatigue Syndrome, Chronic, Stress, Psychological, Chronic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resistance trainingBehavioural
Participants will complete a 2-days-a-week training routine: Resistance training (RT, 50-75% 1RM (one-repetition maximum), 4 sets, 8-12 repetitions, 4 exercises). The warn up include Light Intensity Continuous Training (8-10 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by Physiotherapists and Graduated in Sports Sciences.
Standard careBehavioural
This group will be allocated to standard care and therefore no supervised exercise regimen according to scientific guidelines for general physical activity and return to sport provided by the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease.
| Study group | Role | What they receive |
|---|---|---|
| Exercise | Experimental | Resistance training Receives: Behavioral: Resistance training |
| Standard care | Active comparator | Non-supervised ACSM exercise guidelines Receives: Behavioral: Standard care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in Cardiorespiratory fitness
Measured with an incremental VO2 protocol on exercise bike by COSMED Quark CPET plus OMNIA (COSMED®, Rome, Italy)
Measured: Baseline, 6 Weeks and 12 Weeks
Secondary outcomes (33)
Changes in Post-COVID manifestations
Questionnaires that sought information about symptoms related to COVID-19 will be administrate. It is a dichotomous scale (Yes/No), that reflects symptoms, functional limitations, and clinical characteristics (i.e., nausea/vomiting, impaired visual acuity or blurry vision, anosmia, dizziness, depression, chills, weakness, musculoskeletal pain, palpitations/tachycardia, change of appetite, frustration, cognitive involvement, anxiety/irritability, dryness, impaired concentration, and headache)
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in Blood samples analysed for markers related to low grade inflammation
Including ENA-78, GCSF, GM-CSF, GRO, GRO-alpha, I-309, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 p40/p70, IL-13, IL-15, IFN-gamma, MCP-1, MCP-2, MCP-3, MCSF, MDC, MIG, MIP-1delta, RANTES, SCF, SDF-1, TARC, TGF-beta1, TNF-alpha, TNF-beta, EGF, IGF-I, Angiogenin, Oncostatin M, Thrombopoietin, VEGF-A, PDGF BB, Leptin in (arbitrary units).
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in pulse wave velocity
Measuring pulse wave velocity (m/seg) by VaSera VS 2000 (Fukuda Denshi, Japan)
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in cardio-ankle vascular index (CAVI)
Measuring Cardio-Ankle Vascular Index (%) by VaSera VS 2000 (Fukuda Denshi, Japan)
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in Energy expenditure
Measuring by COSMED Q-NRG+ plus OMNIA (COSMED®, Rome, Italy)
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in bone mineral density measured with DXA
Measuring in bone mineral density (g)
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in fat mass measured with DXA
Measuring in fat mass (%)
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in lean mass measured with DXA
Measuring in lean mass (kg)
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in Fat max oxidation rate
Measured with an incremental VO2 protocol on exercise bike by COSMED k-5 plus OMNIA (COSMED®, Rome, Italy)
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in Dynamic and isometric strength
Muscular fitness testing (legs, chest, arms, hip and grip)
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in Axial accelerometer-based physical activity monitors
Free-living physical activity is measured using axial accelerometer-based physical activity monitors (AX3; Axivity, Newcastle upon Tyne, UK)
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in blood samples analysed for markers related to oxidative stress
Including catalase, glutathione peroxidase, peroxidase, glutathione reductase in arbitrary units.
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in serum metabolic profiles
Utrahigh-performance liquid chromatography (UHPLC)-time of flight-MS based platforms analyzing methanol and chloroform/methanol serum extracts will be combined with the lipids measurement using an UHPLC-single quadrupole-MS based analysis in arbitrary units. Explained fraction of variance and the goodness of prediction will be calculated.
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in creatinine kinase
Creatinine kinase levels (units per liter)
Measured: Baseline
Changes in total troponins levels (ng/mL)
Total troponins levels (ng/mL)
Measured: Baseline
Changes in D-dimer
D-dimer (ng/mL)
Measured: Baseline
Changes in thyroid function parameters
T3 and T4 levels (μg/dL)
Measured: Baseline
Changes in liver function
ALT in (U/L), AST and GGT in (U/L)
Measured: Baseline
Changes in renal function
Urea (mmol/L), sodium (mmol/L), potassium (mmol/L), chloride (mmol/L), calcium (mmol/L), inorganic phosphorus (mmol/L) and uric acid (mmol/L)
Measured: Baseline
Changes in haematology parameters
White Blood Cells and Red Blood Cells (cell characterization)
Measured: Baseline
Changes in cognitive status
Montreal Cognitive Assessment (MOCA) will be used as an indicator of cognitive status. Scores range between 0 and 30. A score of 26 or over is considered to be normal
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in visual attention and task switching
The Trail Making Test will be used as an indicator of visual scanning, graphomotor speed, and executive function. This test consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in Quality of life
Two summary scores are reported from the EuroQOL EQ-5D instrument
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in psychological stress
The 1 Item Statistics Canada Stress Question (SCSQ) will be used. The SCSQ is a 1-item question with a possible scoring of 0 to 10, with higher scores indicating more stress.
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in physical health symptomology
A Physical Health item will be used in the baseline. The scoring range is 0-13, with higher numbers indicating experiencing more negative physical health symptoms.
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in psychological distress
The 10 Item Kessler Psychological Distress Scale will be used. Scores range from 10-50, with higher scores indicating more symptoms or more frequent experience of those symptoms.
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in depressive symptomology
The 10 Item Center for Epidemiologic Studies Depression Scale (CES-D) will be used in the baseline survey, and will be in each weekly survey to track changes in the CES-D over the study period. The possible range in scores is 0 to 30 depending on number of symptoms, with those symptoms weighted by frequency experienced in a week. Higher scores indicating more or more frequent symptoms.
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in life satisfaction
A Life Satisfaction item, consisting of three questions, will be used (scored 0-10). Higher scores indicate "the best possible life overall". In addition, 2-follow-up questions asking individuals to rate their physical and mental/emotional health on a five point scale from poor to excellent. Higher scores overall indicate more satisfaction with life.
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in resilience
The Brief Resilience Scale will be used (scores from 1-5). Higher scores indicate the individual perceives they have a better ability to 'bounce back' and recover from stressful events and/or situations.
Measured: Baseline, 6 Weeks and 12 Weeks
Change in pain score using numeric 0-10 rating scale
The numeric rating scale is 0-10 where 0 is no pain, 5 is moderate pain and 10 is the worst pain
Measured: Baseline, 6 Weeks and 12 Weeks
Tracking the amount of exercise variety participants feel they engage in
Using the Perceived Variety in Exercise questionnaire. There are 5 items asking about exercise variety, scored 1 (false) to 6 (true), with a possible score of 5-30; higher scores indicate greater perceived variety.
Measured: Baseline, 6 Weeks and 12 Weeks
Changes in physical activity levels
Metabolic Equivalents (METs) throughout a week, including activity for work, during transport and leisure time, using the self-reported general physical activity questionnaire (GPAQ).
Measured: Baseline, 6 Weeks and 12 Weeks
Including Changes in mononuclear cells of peripheral blood (sub-sample 40 participants)
CD4, CD8, PD1, CD62L, LKRG1, CD28, CD57, CD163, CD119, CD56, CD116, CD66b, CD11b, and CD14 by flow cytometry
Measured: Baseline, 6 Weeks and 12 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2021
- Study start8 Mar 2021
- Primary completion18 Sep 2022
- Study completion18 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Covid19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad Pública de Navarra
- Sponsor type
- University, hospital or other
- Collaborators
- Fundacion Miguel Servet, Complejo Hospitalario de Navarra
- Responsible party
- Sponsor
- Investigators
- Mikel Izquierdo, Ph.D, Study chair, Universidad Publica de Navarra
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04797871
- Sponsor's protocol ID
- PI_2020/140
- Acronym
- EXER-COVID
- Status last verified
- Jul 2022
- First submitted
- 8 Mar 2021
- Last updated
- 2 Nov 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Garcia-Alonso N, Izquierdo M, Arasanz H, Ramirez-Velez R. Immunological effects of supervised exercise in long COVID in adults: A secondary analysis of a randomized crossover trial. Physiol Rep. 2026 Sep;14(17):e71031. doi: 10.14814/phy2.71031.
PubMed 42665974Ramirez-Velez R, Oteiza J, de Tejerina JMCF, Garcia-Alonso N, Legarra-Gorgonon G, Oscoz-Ochandorena S, Arasanz H, Garcia-Alonso Y, Correa-Rodriguez M, Izquierdo M. Resistance training and clinical status in patients with postdischarge symptoms after COVID-19: protocol for a randomized controlled crossover trial "The EXER-COVID Crossover Study". Trials. 2022 Aug 9;23(1):643. doi: 10.1186/s13063-022-06608-y.
PubMed 35945634
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Resistance Training Intervention on the Clinical Status in Patients With Post Discharge Symptoms After Covid-19: The "EXER-COVID Study"
- ClinicalTrials.gov ID
- NCT04797871
- Acronym / sponsor ID
- EXER-COVID / PI_2020/140
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Universidad Pública de NavarraUniversity, hospital or other
- Collaborators
- Fundacion Miguel Servet, Complejo Hospitalario de Navarra
- Study start
- 8 Mar 2021 (actual)
- Primary completion
- 18 Sep 2022 (actual)
- Study completion
- 18 Sep 2022 (actual)
- First posted
- 15 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
COVID-19 survivors commonly exhibit a marked extra-respiratory complication affecting the cardiac (arrhythmias and myocardial injury), renal (acute kidney injury), gastrointestinal, nervous (neuropathy, encephalopathy), endocrine and musculoskeletal (weakness, pain, and fatigue) systems. In this context, several studies have found that resistance training intervention promotes important health-related benefits, including cardiac function, compared to aerobic exercise training. Other exercise adaptations include increased skeletal muscle metabolism function, yet physio/psychological adaptations are known to be limited in COVID-19 survivors. Hence, given that resistance training intervention is implemented in a manner that is tolerable to the individual patient, it may be a potential beneficiary "personalized" rehabilitation treatment for patients with COVID-19 syndrome ambulatory.
The "EXER-COVID Clinical Study" project aims at determining the role of personalized exercise intervention in the treatment of post-COVID-19 syndrome ambulatory patients.
Detailed description
100 patients will be recruited and undergo baseline testing, including examination, immune systems, biochemistry markers, ECG, DXA, metabolic/respiratory function, VO2max, muscular fitness, lipidomic/inflammatory/oxidative markers and psychological outcomes.
After baseline testing, participants will be randomly allocated into one group receiving standard of care (control group) or a group performing personalized resistance training intervention two times a week over a period of 6 weeks. The randomization procedure involves a computer-generated block randomization schedule in a ratio of 1:1 stratified by an independent person. Following the 8-week intervention period (with a 1-week washout period), both groups will complete a series of follow-up tests (as baseline testing). A 12-week follow-up experimental day is also planned in order to evaluate physio/psychological changes.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Exercise | Experimental | Behavioral: Resistance trainingResistance training |
| Standard care | Active comparator | Behavioral: Standard careNon-supervised ACSM exercise guidelines |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Age ≥ 18 years
- SARS-CoV-2 diagnosed using real-time reverse transcriptase polymerase chain reaction (PCR) tests or positive for SARS-CoV-2 virus antigen >90 days before randomization.
- Still present a chronic symptomatic phase lasting >90 days since debut of symptoms.
- Have not been hospitalized.
- There is no evidence on clinical records of pneumonia or any other organ failure related to SARS-CoV-2.
Key exclusion criteria (6 listed)
- Pregnancy or breast-feeding.
- Present atrial fibrillation.
- Diagnosed with acute myocarditis.
- Health conditions that prevent participating in the exercise intervention
- Patients who cannot undergo VO2max (e.g. acute heart attack or unstable angina, aortic stenosis, acute endocarditis / pericarditis, uncontrolled high blood pressure, acute thromboembolism, severe heart failure, respiratory failure and uncontrolled acute decompensated diabetes mellitus or low blood sugar).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resistance trainingParticipants will complete a 2-days-a-week training routine: Resistance training (RT, 50-75% 1RM (one-repetition maximum), 4 sets, 8-12 repetitions, 4 exercises). The warn up include Light Intensity Continuous Training (8-10 min, 65-70% HRR). Progressions will be individualized and consistent with patient tolerance. Sessions will be supervised by Physiotherapists and Graduated in Sports Sciences. | Behavioural | Exercise |
| Standard careThis group will be allocated to standard care and therefore no supervised exercise regimen according to scientific guidelines for general physical activity and return to sport provided by the ACSM guidelines for Chronic Obstructive Pulmonary Disease and Cardiovascular Disease. | Behavioural | Standard care |
Primary outcome
Changes in Cardiorespiratory fitness
Time frame: Baseline, 6 Weeks and 12 Weeks
Measured with an incremental VO2 protocol on exercise bike by COSMED Quark CPET plus OMNIA (COSMED®, Rome, Italy)
33 secondary outcomes
Changes in Post-COVID manifestations
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in Blood samples analysed for markers related to low grade inflammation
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in pulse wave velocity
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in cardio-ankle vascular index (CAVI)
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in Energy expenditure
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in bone mineral density measured with DXA
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in fat mass measured with DXA
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in lean mass measured with DXA
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in Fat max oxidation rate
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in Dynamic and isometric strength
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in Axial accelerometer-based physical activity monitors
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in blood samples analysed for markers related to oxidative stress
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in serum metabolic profiles
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in creatinine kinase
Time frame: Baseline
Changes in total troponins levels (ng/mL)
Time frame: Baseline
Changes in D-dimer
Time frame: Baseline
Changes in thyroid function parameters
Time frame: Baseline
Changes in liver function
Time frame: Baseline
Changes in renal function
Time frame: Baseline
Changes in haematology parameters
Time frame: Baseline
Changes in cognitive status
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in visual attention and task switching
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in Quality of life
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in psychological stress
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in physical health symptomology
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in psychological distress
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in depressive symptomology
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in life satisfaction
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in resilience
Time frame: Baseline, 6 Weeks and 12 Weeks
Change in pain score using numeric 0-10 rating scale
Time frame: Baseline, 6 Weeks and 12 Weeks
Tracking the amount of exercise variety participants feel they engage in
Time frame: Baseline, 6 Weeks and 12 Weeks
Changes in physical activity levels
Time frame: Baseline, 6 Weeks and 12 Weeks
Including Changes in mononuclear cells of peripheral blood (sub-sample 40 participants)
Time frame: Baseline, 6 Weeks and 12 Weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2022.
- Derived from this study: PubMed 42665974Garcia-Alonso N, Izquierdo M, Arasanz H, Ramirez-Velez R. Immunological effects of supervised exercise in long COVID in adults: A secondary analysis of a randomized crossover trial. Physiol Rep. 2026 Sep;14(17):e71031. doi: 10.14814/phy2.71031.
- Derived from this study: PubMed 35945634Ramirez-Velez R, Oteiza J, de Tejerina JMCF, Garcia-Alonso N, Legarra-Gorgonon G, Oscoz-Ochandorena S, Arasanz H, Garcia-Alonso Y, Correa-Rodriguez M, Izquierdo M. Resistance training and clinical status in patients with postdischarge symptoms after COVID-19: protocol for a randomized controlled crossover trial "The EXER-COVID Crossover Study". Trials. 2022 Aug 9;23(1):643. doi: 10.1186/s13063-022-06608-y.
- Individual participant dataSharing planned: No
Related trials for Covid19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mikel Izquierdo, Ph.D study chair
Universidad Publica de Navarra
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Resistance training in people with Covid19 and SARS-CoV2, run by Universidad Pública de Navarra at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in Cardiorespiratory fitness (time frame: Baseline, 6 Weeks and 12 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04797871, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2022.